What SEC filings does Vir Biotechnology, Inc. submit to the SEC?

Vir Biotechnology, Inc. (VIR) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VIR?

A Form 4 for VIR discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Vir Biotechnology, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VIR?

The 10-K is Vir Biotechnology, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VIR SEC filings directly on EDGAR?

You can view all historical Vir Biotechnology, Inc. filings on the SEC EDGAR company page for VIR. Each filing card on this page links directly to the original SEC document.

How often does Vir Biotechnology, Inc. file with the SEC?

Vir Biotechnology, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VIR shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

VIR SEC Filing News — Vir Biotechnology, Inc.

Latest SEC filings for Vir Biotechnology, Inc. (VIR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibod…

Sector: Healthcare Industry: Biotechnology Market Cap: $1.7B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for VIR currently lean bearish. Of the 20 filing records displayed, 2 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

VIR Filing Activity Snapshot 2026-05-28 — 2026-10-14

Insider Transactions (Form 4)

0 buys vs 2 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$315.2K

O'Byrne Jason · 2026-09-09

28,333 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 5 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 5 filings in this group are Form 4s for Vir Biotechnology, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 5 insider filings shown, the breakdown is 2 compensation award, 2 open-market sale and 1 other reported transaction. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×2: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Other reported transaction ×1: The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Form 4 Other reported transaction Tax / Compensation Filing 2026-08-12

VIR insider Form 4 filed for equity award, exercise, or tax withholding

MORE ROBERT J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	8,000	—	—
`J`	Other transaction	8,000	—	—

Filing: Form 4 (Insider Transaction) Insider: MORE ROBERT J (Director) Shares: 16,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

VIR insider Form 4 filed for equity award, exercise, or tax withholding

Coughlin Timothy (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	8,000	—	—
`A`	Compensation award	8,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	16,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	16,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Coughlin Timothy (Director) Shares: 16,000

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-02

VIR insider Napolitano Janet (Director) sold 3,200 shares (~$30.2K)

Napolitano Janet, listed as Director at Vir Biotechnology, Inc., reported an open-market sale of 3,200 VIR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,200	$9.45	$30.2K

Filing: Form 4 (Insider Transaction) Insider: Napolitano Janet (Director) Shares: 3,200 Est. Value: $30.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-02

VIR insider Sabatini Brent (SVP, Chief Accounting Officer) sold 379 shares (~$3.6K)

Sabatini Brent, listed as SVP, Chief Accounting Officer at Vir Biotechnology, Inc., reported an open-market sale of 379 VIR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	379	$9.45	$3.6K

Filing: Form 4 (Insider Transaction) Insider: Sabatini Brent (SVP, Chief Accounting Officer) Shares: 379 Est. Value: $3.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

VIR insider Form 4 filed for equity award, exercise, or tax withholding

Sigal Charles Elliott (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	8,000	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	16,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Sigal Charles Elliott (Director) Shares: 8,000

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 8 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Vir Biotechnology, Inc. has 8 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-17

VIR Form 144 filed for proposed insider sale by O'Byrne Jason (19,357 shares) ~$212.9K

O'Byrne Jason filed a Form 144 with the SEC indicating intent to sell VIR (Vir Biotechnology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: O'Byrne Jason Shares: 19,357 Est. Value: $212.9K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-09

VIR Form 144 filed for proposed insider sale by O'Byrne Jason (28,333 shares) ~$315.2K

Filing: Form 144 (Proposed Sale Notice) Insider: O'Byrne Jason Shares: 28,333 Est. Value: $315.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-25

VIR Form 144 filed for proposed insider sale by O'Byrne Jason (23,148 shares) ~$242.6K

Filing: Form 144 (Proposed Sale Notice) Insider: O'Byrne Jason Shares: 23,148 Est. Value: $242.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-24

VIR Form 144 filed for proposed insider sale by O'Byrne Jason (14,352 shares) ~$142.1K

Filing: Form 144 (Proposed Sale Notice) Insider: O'Byrne Jason Shares: 14,352 Est. Value: $142.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-21

VIR Form 144 filed for proposed insider sale by O'Byrne Jason (25,000 shares) ~$245.3K

Filing: Form 144 (Proposed Sale Notice) Insider: O'Byrne Jason Shares: 25,000 Est. Value: $245.3K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-29

VIR Form 144 filed for proposed insider sale by Ramasastry Saira (16,000 shares) ~$165.1K

Ramasastry Saira filed a Form 144 with the SEC indicating intent to sell VIR (Vir Biotechnology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Ramasastry Saira Shares: 16,000 Est. Value: $165.1K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-01

VIR Form 144 filed for proposed insider sale by Sabatini Brent (379 shares) ~$3.6K

Sabatini Brent filed a Form 144 with the SEC indicating intent to sell VIR (Vir Biotechnology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Sabatini Brent Shares: 379 Est. Value: $3.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-06-01

VIR Form 144 filed for proposed insider sale by Napolitano Janet (3,200 shares) ~$30.2K

Napolitano Janet filed a Form 144 with the SEC indicating intent to sell VIR (Vir Biotechnology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Napolitano Janet Shares: 3,200 Est. Value: $30.2K

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Vir Biotechnology, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14